TY - GEN AU - Esteva,Francisco J AU - Wang,Jing AU - Lin,Feng AU - Mejia,Jaime A AU - Yan,Kai AU - Altundag,Kadri AU - Valero,Vicente AU - Buzdar,Aman U AU - Hortobagyi,Gabriel N AU - Symmans,W Fraser AU - Pusztai,Lajos TI - CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer SN - 1465-542X PY - 2008///0306 KW - Adult KW - Aged KW - Antibodies, Monoclonal KW - administration & dosage KW - Antibodies, Monoclonal, Humanized KW - Antineoplastic Combined Chemotherapy Protocols KW - Biomarkers, Tumor KW - metabolism KW - Biopsy, Fine-Needle KW - Breast Neoplasms KW - drug therapy KW - CD40 Antigens KW - Cyclophosphamide KW - Epirubicin KW - Female KW - Fluorouracil KW - Gene Expression Profiling KW - Gene Expression Regulation, Neoplastic KW - Humans KW - Mastectomy KW - methods KW - Mastectomy, Modified Radical KW - Mastectomy, Segmental KW - Middle Aged KW - Neoadjuvant Therapy KW - Neoplasm Staging KW - Neoplasm, Residual KW - Paclitaxel KW - Predictive Value of Tests KW - RNA, Messenger KW - Receptor, ErbB-2 KW - genetics KW - Signal Transduction KW - Transcription, Genetic KW - Trastuzumab KW - Treatment Outcome KW - Up-Regulation N1 - Publication Type: Journal Article; Research Support, Non-U.S. Gov't UR - https://doi.org/10.1186/bcr1836 ER -